Polymorphism of hemostasis system factors FII, FV, FGB, PAI-1 and platelet receptors ITGА2, ITGB3 genes in patients with atrial fibrillation (pilot study)

   Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, accounting for approximately one-third of hospitalizations for heart rhythm disorders. AF is associated with an increased risk of death, stroke and other thrombotic complications, impaired quality of life, decreased exercise tolerance, and left ventricular dysfunction. Laboratory diagnosis of predisposition to the occurrence of thrombotic complications is carried out by determining the polymorphism of genes of hemostasis factors. Of particular interest is the identification of cases of congenital thrombophilia resulting from molecular defects in the hemostasis system or its inhibition processes. The study included 41 healthy volunteers and 52 patients with AF: paroxysmal and persistent forms. Of these, 8 patients (15.38 %) developed thrombotic complications against the background of adequate anticoagulant therapy. Genetic methods of investigation included DNA isolation and examination of polymorphic variants of genes of the hemostasis system and platelet receptors using real-time polymerase chain reaction method. Genotype frequencies were compared using Pearson’s χ² criterion with Yates correction (Y). The nature of associations of genotypes with thrombotic complications was assessed using odds ratios (OR) and their 95% confidence interval (95 % CI). Comparative analysis of hemostasis system factors genotypes: rs1799963 FII, rs6025 FV, rs1800790 FGB, rs1799899 PAI-1 and platelet receptors: rs1126643 ITGA2, rs5918 ITGB3 in patients with atrial fibrillation and controls showed no significant differences. The studied genetic polymorphisms of hemostasis system factors and platelet receptors were not associated with the risk of thrombotic complications in patients with atrial fibrillation.

1. Nedoruba E. A., Tajutina T. V., Egorov V. N., Stepanenko A. F. Osobennosti farmakoterapii fibrillyatsii predserdiy u patsiyentov pozhilogo i starcheskogo vozrasta v usloviyakh polikliniki [Peculiarities of pharmacotherapy of atrial fibrillation in elderly and senile patients in outpatient settings]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2016; (2): 70-78. (In Russ.)

2. Ogurkova O. N., Suslova T. E., Batalov R. E. Issledovaniye spontannoy i stimulirovannoy agregatsii trombotsitov u patsiyentov s raznymi tipami fibrillyatsii predserdiy [Study of spontaneous and stimulated platelet aggregation in patients with different types of atrial fibrillation]. Klinicheskaya laboratornaya diagnostika [Russian Clinical Laboratory Diagnostics Journal]. 2021; 66 (1): 35-41. (In Russ.)

3. Evtushenko A. V., Evtushenko V. V., Petlin K. A., Belenkova E. M. Sposob dostizheniya transmuralʹnosti povrezhdeniya miokarda predserdiy pri lechenii nadzheludochkovykh aritmiy i ustroystvo dlya yego osushchestvleniya [A method for achieving transmurality of atrial myocardial damage in the treatment of supraventricular arrhythmias and a device for its implementation]. Patent na izobreteniye [Patent] RU 2394522 C2. (In Russ.)

4. Evtushenko A. V., Evtushenko V. V., Pavljukova E. N., Popov S. V. Monopolyarnaya radiochastotnaya ablatsiya dlitelʹno persistiruyushchey fibrillyatsii predserdiy u patsiyentov s porokami serdtsa i khronicheskoy serdechnoy nedostatochnostʹyu [Monopolar radiofrequency ablation of long persistent atrial fibrillation in patients with cardiac defects and chronic heart failure]. Tomsk: NII kardiologii, Tomskiy NIMTS [Cardiology Research Institute, Tomsk National Research Medical Centre], 2019; 238 p. (In Russ.)

5. Rossiyskiye klinicheskiye rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy Russian Clinical Guidelines for the [Diagnosis, Treatment and Prevention of Venous Thromboembolic Complications]. Flebologiya [Flebologiya]. 2015; (4): 2-52. (In Russ.)

6. Zatejshhikov D. A., Zotova I. V., Dankovceva E. N., Sidorenko B. A. Klinicheskiye i geneticheskiye aspekty mertsatelʹnoy aritmii: sovremennoye sostoyaniye problem [Clinical and genetic aspects of atrial fibrillation: current status of the problem]. Kremlevskaya medicina. Klinicheskiy vestnik [Kremlin medicine journal]. 2010; (2):6-10. (In Russ.)

7. Hatzinikolaou-Kotsakou E., Kartasis Z., Tziakas D. et al. Atrial fibrillation and hypercoagulability: dependent on clinical factors or/ and on genetic alterations? J Thromb Thrombolysis.2003; 16: 155–161.

8. Berge E., Haug K., Sandset E. C. et al. The Factor V Leiden, Prothrombin Gene 20210GA, Methylenetetrahydrofolate Reductase 677CT and Platelet Glycoprotein IIIa 1565TC Mutations in Patients With Acute Ischemic Stroke and Atrial Fibrillation. Stroke. 2007; 38: 1069–1071.

9. Lugacheva Yu. G., Kulagina I. V., Kovalev I. A., Krivoschekov Y. V., Yanulevich O. S., Suslova T. E. Faktory riska tromboticheskikh oslozhneniy u patsiyentov s funktsionalʹno yedinstvennym zheludochkom serdtsa [Risk factors of thrombotic complications in patients with single functional ventricle]. Rossiyskiy Vestnik Perinatologii i Pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2019; 64 (2): 68-74. (In Russ.) doi: 10.21508/1027-4065-2019-64-2-68-74

10. Gokce M., Ucar F., Kucukosmanoglu M. et al. Factor V Leiden mutation and its relation to left atrial thrombus in chronic nonrheumatic atrial fibrillation. Jpn Heart J. 2003; 44 (4): 481-491.

11. Loginova A. I., Kropacheva E. S., Maykov E. B., Balakhonova T. V. Venoznyye trombozy posle kateternykh ablyatsiy. Osobennosti diagnostiki, effektivnostʹ i bezopasnostʹ razlichnykh rezhimov antikoagulyantnoy terapii [Venous thrombosis after catheter ablation. Features of diagnostics, efficacy and safety of different regimens of anticoagulant therapy]. Kardiologicheskiy vestnik [Russian Cardiology Bulletin]. 2019; 14 (1): 12-17. (In Russ.). doi: 10.17116/Cardiobulletin20191401112

12. Agibova N. E., Boeva O. I. Prognozirovaniye riska tromboembolicheskikh oslozhneniy u patsiyentov s neklapannoy fibrillyatsiyey predserdiy [Prediction of risk of thromboembolic complications in patients with non-valvular atrial fibrillation]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2017; (5): 91-99. (In Russ.)

13. Aksyutina N. V., Nikulina S. Ju., Shul’man V. A. et al. Vzaimosvyazʹ polimorfizma gena beta-tsepi fibrinogena s razvitiyem ostrogo narusheniya mozgovogo krovoobrashcheniya v semʹyakh bolʹnykh s fibrillyatsiyey predserdiy [Correlation of polymorphism of fibrinogen beta-chain gene and stroke in families of patients with atrial fibrillation]. Vestnik aritmologii [Journal of Arrhythmology]. 2013; (71): 26-29. (In Russ.)

14. Kucukarabaci B., Gunes H. V., Ozdemir G. et al. Investigation of Association between Plasminogen Activator Inhibitor Type-1(PAI-1) Gene 4G/5G Polymorphism Frequency and Plasma PAI-1 Enzyme Activity in Patients with Acute Stroke. Genetic Testing. 2008; (12): 443–451.